HOME >> BIOLOGY >> NEWS
Long-Time NIH Grantee Wins Nobel Prize In Chemistry

Dr. Paul D. Boyer, a long-time NIH grantee, is one of three recipients of the 1997 Nobel Prize in chemistry. Boyer, who is a professor emeritus of biochemistry at the University of California, Los Angeles, received over $4.4 million in research grant support from NIH between 1948 and 1996. The vast majority of this support was from the National Institute of General Medical Sciences, with other funding coming from the National Institute of Diabetes and Digestive and Kidney Diseases.

Dr. Jens C. Skou of Aarhus University in Denmark, one of the other prize recipients, received support from NIH's National Institute of Neurological Disorders and Stroke in the early 1960's.

"The Nobel Prize recognizes Dr. Boyer for a lifetime spent investigating the molecular mechanism by which ATP--the cellular energy that drives all biological reactions--is formed," said Dr. Marvin Cassman, NIGMS Director. "Determining how ATP is synthesized has been a central problem in biology for decades and is at the core of an understanding of metabolic processes in the cell. Dr. Boyer has been a key contributor to the molecular understanding of ATP synthesis."

Since the early 1950's, Boyer has sought to understand the inner workings of ATP synthase, the enzyme he calls the "splendid molecular machine" that produces ATP. The enzyme is a complex protein rooted in the inner membranes of cellular structures called mitochondria, the "powerhouses of the cell."

Over several decades, Boyer developed a model of how the various subunits of the enzyme work together like gears, levers, and ratchets to generate cellular e
'"/>

Contact: Alisa Zapp or Ann Dieffenbach
pub_info@nigms.nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
15-Oct-1997


Page: 1 2

Related biology news :

1. Press workshop Life, a Nobel Story
2. Structure of a Nobel-prize winning molecule: Aquaporin
3. Marie Curie Nobel Centennial Celebration of Women in Science
4. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
5. Illinois professor wins Nobel Prize
6. UT Southwestern Nobelists find protein structure that may help fight high cholesterol
7. Kurt Wthrich of The Scripps Research Institute wins 2002 Nobel Prize in Chemistry
8. Sydney Brenner, Molecular Sciences Institute founder, awarded the Nobel Prize
9. Salk Institute professor Sydney Brenner receives 2002 Nobel Prize for medicine
10. NLM exhibit features Nobelist Joshua Lederberg
11. Günter Blobel wins 1999 Nobel Prize for physiology or medicine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Long Time NIH Grantee Wins Nobel Prize Chemistry

(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... market will grow moderately through 2023 as the aging ... awareness of dental biomaterials all spur procedure volumes. Growth ... China and India ... procedures within reach for a larger proportion of the ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: